Ajay Mitter, MD
Hematology & Oncology · San Antonio, TXNPI 1174587307
Payments from drug & device makers
Across 153 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$490
- Merck$269
- Puma Biotechnology, Inc.$269
- Novartis$236
- Amgen$220
- Pfizer$211
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,97396%
- Education$1104%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 19 | $490 |
| Merck | 14 | $269 |
| Puma Biotechnology, Inc. | 10 | $269 |
| Novartis | 11 | $236 |
| Amgen | 13 | $220 |
| Pfizer | 10 | $211 |
| Johnson & Johnson(2 entities) | 8 | $136 |
| Bayer | 7 | $128 |
| AbbVie | 7 | $124 |
| AVEO Pharmaceuticals, Inc. | 4 | $115 |
| Incyte Corporation | 4 | $76 |
| Sanofi | 4 | $72 |
| Eisai Inc. | 4 | $70 |
| Bristol Myers Squibb | 3 | $62 |
| Dova Pharmaceuticals | 4 | $56 |
| GSK | 3 | $53 |
| Daiichi Sankyo Inc. | 2 | $49 |
| EMD Serono, Inc. | 3 | $47 |
| Lilly USA, LLC | 3 | $46 |
| Boehringer Ingelheim | 2 | $38 |
| AstraZeneca | 1 | $35 |
| Seagen Inc. | 2 | $33 |
| Recordati_rare_diseases_inc. | 1 | $29 |
| Astellas Pharma US Inc | 2 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Sobi, Inc | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $20 |
| Morphosys, US Inc. | 1 | $17 |
| Array Biopharma Inc | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Mylan Institutional Inc. | 1 | $12 |
| Gilead | 1 | $12 |
| Exelixis Inc. | 1 | $12 |
How this compares
$3,082 in reported general payments places this provider in the 35th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in San Antonio
- Kyriakos PapadopoulosSan Antonio$18.5M
- Drew RascoSan Antonio$14.1M
- David SommerhalderSan Antonio$10.4M
- Emmalind AponteSan Antonio$4.4M
- Manuel SantiagoSan Antonio$3.9M
- Paul ShaughnessySan Antonio$3.7M
- Ildefonso Rodriguez RiveraSan Antonio$2.7M
- Sharon WilksSan Antonio$2.5M
- Elias JabbourHouston$264.1M
- Luhua WangHouston$79.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.